Conejo Valley-based Acelyrin, a clinical, pre-revenue biotechnology company, reported its financial results for the full year 2023 on March 28. According to the March 28 report, the company’s net loss for the full year ended Dec. 31 was $381.6 million, compared to $64.8 million for 2022. The company primarily saw expenses increase in research and
Acelyrin's headquarters in Agoura Hills. (courtesy photo) Conejo Valley-based Acelyrin saw shares plummet more than 30% on Nov. 28 after the biotechnology startup announced an error in one of its trials for its main treatment. Acelyrin, which is a part of Westlake Village BioPartners investing portfolio, disclosed there was a programming error in a drug